Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA 2802205 C · Owner: Seattle Genetics, Inc. · Inventors: Senter, Peter D.; Doronina, Svetlana; Toki, Brian E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one etnbodiment the Ligand is an Antibody. Drug- Linker compounds and Drug compounds are also disclosed. Methods for treating cancer an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 2003 and granted January 19, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.